diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia |
|
|
| Recruiting | 1/2 | 50 | US, RoW | AP-SA02, Placebo | Armata Pharmaceuticals, Inc., United States Department of Defense | Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus | 12/24 | 03/25 | | |
